CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, as CD34+/CD38− human CML cells express high levels of the CD25/IL2 receptor, inhibition of IL2 synthesis by cyclosporine in combination with Dasatinib was tested in a phase I clinical trial with the hope to eliminate CD25+ LSCs (NCT01426334).